Bioprocessing of Viral Vectors and Vaccines

主席在上一任期内取得的主要成就包括：-将流感种子储备的产生从几个月缩短到几周，以便能够利用细胞培养技术和逆向工程快速生产疫苗，以应对大流行的情况。-开发和技术转让用于保护埃塞俄比亚牲畜的防新城疫腺病毒载体疫苗的生产工艺。-在悬浮液和无血清培养基中运行的Vero细胞系生产平台的先进工艺开发，用于生产针对埃博拉病毒、艾滋病毒和SARS-CoV-2候选疫苗的重组水泡性口炎病毒载体疫苗。-在加拿大和国外进行能力建设和高素质人员培训，以支持应对新出现和再出现的传染病的准备计划。基于这些有影响力的成果，这些成果目前被行业用于加速开发针对COVID-19大流行的载体疫苗，拟议的CRC一级研究项目病毒载体和疫苗的生物过程科学与技术侧重于复杂生物系统的逆向工程和细胞/病毒相互作用的动力学，以设计安全的先进制造工艺。用于体内基因编辑的有效且具有成本效益的疫苗和输送系统。一种系统方法，整合1)基因组尺度的病毒和细胞生物平台重新设计，2)持续的过程加速和强化，3)过程分析技术和数据科学，以支持提供高价值药物，以应对新出现和再出现的传染病。该研究项目建立在与工业和机构合作伙伴的长期合作基础上，以支持新技术的转化和高价值病毒产品的商业化。该计划还旨在为HQPs提供扎实的培训，以满足加拿大生物制造业的需求，并在先进疫苗制造的战略领域建立持续的能力。

The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering.- Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines.- Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases.Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.